ArticleInterdisciplinary cardiovascular and thoracic surgery2025
Robotic Hybrid Ablation with Novel Epicardial Electrophysiological Mapping: Impact on Atrial Fibrillation Therapy.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the first use of the EnSite X system for intraoperative electrophysiological mapping during a robotic hybrid ablation (ROK-AF procedure) for long-standing persistent atrial fibrillation. Epicardial ablation targets were identified through epicardial mapping, and post-ablation electrical silencing was validated using the mapping system. Unlike conventional electrophysiological mapping systems, the orientation-independent omnipolar technology in EnSite X provides directional activation vectors, high-resolution electrograms, and peak frequency analysis, thereby enhancing substrate characterization. Post-ablation mapping confirmed the successful silencing of the posterior left atrial wall, demonstrating EnSite X's efficacy in real-time guidance for hybrid atrial fibrillation ablation and its potential to enhance robotic surgical workflows, potentially yielding more precise ablations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.